VIP (Vasoactive Intestinal Peptide): What the Research Actually Shows

What is VIP?

Vasoactive intestinal peptide, usually shortened to VIP, is a small signaling peptide that the human body produces naturally. It was first identified for its effects on the gut and blood vessels, which is where its name comes from, but researchers have since learned that it acts throughout the body as a messenger between the nervous and immune systems.

Because it occurs naturally, VIP is not a foreign drug in the usual sense. Interest in it as a therapeutic centers on situations where the body's own VIP signaling may be insufficient or where supplementing it might help calm overactive inflammation. A synthetic form, aviptadil, has been used in clinical research and is the basis for the most rigorous human studies to date.

How it works

The foundational understanding of VIP's role comes from a body of immunology research, including a key review on its significance in immunomodulation. In that work, VIP is described as an anti-inflammatory and immunoregulatory signal: it can shift immune activity away from a pro-inflammatory state and toward a more balanced one, influencing the behavior of immune cells and the chemical messengers they release.

VIP also relaxes smooth muscle and dilates blood vessels and airways, which helps explain why much of the clinical research has focused on the lungs. These are mechanisms observed in laboratory and preclinical settings as well as in early human work, and they describe how VIP may act rather than proving a specific clinical outcome in any given person.

What the research shows

The most controlled human evidence comes from a 2022 randomized controlled trial published in Critical Care Medicine, which tested intravenous VIP (aviptadil) in patients with critical COVID-19 respiratory failure and followed outcomes over 60 days. This represents the largest controlled human dataset for VIP and is significant because randomized controlled trials are the strongest form of clinical evidence. It studied a narrow, severe condition rather than general health.

A 2010 phase 2 clinical trial in the American Journal of Respiratory and Critical Care Medicine examined inhaled VIP in sarcoidosis, an inflammatory lung disease, and found evidence of immunoregulatory effects in humans. This supports the mechanism described above, though phase 2 trials are designed to explore activity and safety rather than to definitively establish benefit.

Taken together, the human research is real but specific and early. It clusters around inflammatory and respiratory conditions, and it does not establish broad, proven benefit for wellness, recovery, or longevity. Much of what is known about VIP outside these trials remains at the mechanism level.

What it's being explored for, and its current status

Based on the available research, VIP is primarily being explored in the context of inflammation and immune regulation, with the clearest human signals in lung-related conditions. Its natural anti-inflammatory role is what draws scientific interest, and ongoing research continues to investigate where, if anywhere, supplementing VIP signaling may be helpful.

It is important to be clear about status. Outside of the specific trial settings described, VIP is investigational and is not an approved therapy in all jurisdictions. The existence of early human data does not mean it is established or appropriate for general use, and it has not been tested in large trials for most of the purposes people might ask about. Anyone considering it should do so only with a qualified physician who can weigh their individual situation.

How Strong Craft Regen approaches VIP

Strong Craft Regen is a coordination and education service, not a prescriber or clinic. We help people understand the evidence honestly, as we have tried to do here, and we coordinate care that is delivered by licensed physicians at Innovita Clinic in Vilnius, Lithuania.

That means any consideration of VIP begins with a physician who evaluates whether it is appropriate for a given person, makes the clinical decisions, and oversees delivery. Our role is to make that process clear, organized, and grounded in what the research actually says, never to promise outcomes the evidence does not support.

If you want to understand whether VIP or another approach fits your situation, the best next step is a conversation. Book a call with us and we will walk you through the options and connect you with the appropriate physician-led care. This article is educational and is not medical advice.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. VIP is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.